Filtered By:
Source: Thrombosis and Haemostasis
Condition: Bleeding

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 164 results found since Jan 2013.

Evaluation of Oral Factor Xa inhibitor-associated Extracranial Bleeding Reversal with Andexanet alfa.
CONCLUSION: We report poor overall outcomes, a low rate of hemostatic effectiveness, and a high rate of ischemic complications and mortality in this retrospective analysis of oral FXa inhibitor reversal with andexanet alfa for extracranial bleeds. More rigorous epidemiological, and ideally randomized studies are needed to determine the role of andexanet alfa for FXa inhibitor-associated bleeding for extracranial hemorrhages, where large variation in severity and presentation exists. PMID: 32738161 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 31, 2020 Category: Hematology Authors: Nederpelt CJ, Naar L, Sylvesterc KW, Barra ME, Roberts RJ, Velmahos GV, Kaafarani HMA, Rosenthal MG, King DR Tags: J Thromb Haemost Source Type: research

Paradoxical Increase of Stroke in Patients with Defect of High Molecular Weight Multimers of the von Willebrand Factors following Transcatheter Aortic Valve Replacement.
CONCLUSION:  MLBCs and CT-ADP > 180 seconds were identified as predictors for ischemic stroke or TIA. The present study suggests that the defects of HMW multimers of the VWFs may contribute not only to bleeding events but also to thrombotic events. PMID: 32726854 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 28, 2020 Category: Hematology Authors: Matsushita K, Marchandot B, Trimaille A, Kibler M, Heger J, Peillex M, Hess S, Grunebaum L, Reydel A, Kindo M, Hoang MT, Sato C, De Poli F, Leddet P, Ohana M, Jesel L, Ohlmann P, Susen S, Morel O Tags: Thromb Haemost Source Type: research

Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?-A Systematic Review.
CONCLUSION:  The higher risk profiles of patients in OSs versus RCTs, and higher rates of both bleeding and mortality not attributable to thromboembolism in patients treated with apixaban 2.5 versus 5 mg twice daily suggest that differences in patient characteristics are additional important contributors to the higher than expected thromboembolic event rates in clinical practice. PMID: 32668484 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 14, 2020 Category: Hematology Authors: de Vries TAC, Hirsh J, Xu K, Mallick I, Bhagirath VC, Eikelboom JW, Ginsberg JS, Kruger PC, Chan NC Tags: Thromb Haemost Source Type: research

Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.
CONCLUSIONS: Persistent systemic inflammatory activity, assessed by repeated IL-6 measurements, is associated with mortality independent of established clinical risk factors and other strong cardiovascular biomarkers in anticoagulated patients with AF. PMID: 32510737 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 7, 2020 Category: Hematology Authors: Aulin J, Hijazi Z, Siegbahn A, Andersson U, Alexander JH, Connolly SJ, Ezekowitz MD, Gersh BJ, Granger CB, Horowitz J, Hylek EM, Lopes RD, Yusuf S, Wallentin L, Oldgren J Tags: J Thromb Haemost Source Type: research

Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project.
CONCLUSION:  In AF patients, the ABC-stroke and ABC-bleeding scores demonstrated similar predictive ability for outcomes beyond stroke and bleeding, including MI, acute HF, a composite of cardiovascular events, and all-cause deaths. This is consistent with nonspecificity of biomarkers that predict "sick" patients or poor prognosis overall. PMID: 32506417 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 6, 2020 Category: Hematology Authors: Camelo-Castillo A, Rivera-Caravaca JM, Marín F, Vicente V, Lip GYH, Roldán V Tags: Thromb Haemost Source Type: research

Female Sex as a Risk Modifier for Stroke Risk in Atrial Fibrillation: Using CHA2DS2-VASc versus CHA2DS2-VA for Stroke Risk Stratification in Atrial Fibrillation: A Note of Caution.
Abstract Stroke prevention is a key clinical concern in the management of patients with atrial fibrillation. Oral anticoagulation treatment reduces the risk of disabling stroke, but the treatment increases the risk of bleeding. For decades, the decision to initiate oral anticoagulation has been guided by clinical risk scoring systems such as the CHADS2 and CHA2DS2-VASc scores. In this narrative review, we focus on the recent discussion of the "Sc" (Sex Category) criterion in the CHA2DS2-VASc score. Epidemiological considerations when assessing stroke rates in cohorts are discussed, and the implications of differen...
Source: Thrombosis and Haemostasis - April 20, 2020 Category: Hematology Authors: Nielsen PB, Overvad TF Tags: Thromb Haemost Source Type: research

Potent and rapid reversal of the von Willebrand Factor Inhibitor Aptamer BT200.
CONCLUSIONS: The results of this study demonstrate that BT101 is an effective reversal agent for BT200. PMID: 32275107 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - April 9, 2020 Category: Hematology Authors: Zhu S, Gilbert JC, Liang Z, Kang D, Li M, Tarantino PM, Jilma B Tags: J Thromb Haemost Source Type: research

Lower versus Standard INR Targets in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
CONCLUSION:  Moderate quality evidence suggests lower INR targets reduce bleeding but increase thromboembolism in AF. The data are dominated by East-Asian studies, limiting generalizability to Western populations. Until higher quality data demonstrate otherwise, an INR range of 2 to 3 should remain standard for thromboembolic prophylaxis in AF. PMID: 31940677 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 14, 2020 Category: Hematology Authors: Pandey AK, Xu K, Zhang L, Gupta S, Eikelboom J, Cook O, McIntyre WF, Lopes RD, Crowther M, Belley-Côté EP, Whitlock RP Tags: Thromb Haemost Source Type: research

Efficacy and Safety of Nonvitamin K Oral Anticoagulants in Patients with Atrial Fibrillation and Cancer: A Study-Level Meta-Analysis.
CONCLUSION:  In AF patients with malignancy, NOACs appear at least as effective as VKAs in preventing thrombotic events and reduce intracranial bleeding. NOACs may represent a valid and more practical alternative to VKAs in this setting of high-risk patients. PMID: 31785599 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 29, 2019 Category: Hematology Authors: Cavallari I, Verolino G, Romano S, Patti G Tags: Thromb Haemost Source Type: research

Prophylaxis of Venous Thromboembolism after Hospital Discharge in Internal Medicine: Findings from the Observational FADOI-NoTEVole Study.
CONCLUSION:  In this study, one in five patients discharged from an Italian IMU received prophylaxis for VTE. The perceived thrombotic risk is significantly related to the use of prophylaxis. PMID: 31634959 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - October 20, 2019 Category: Hematology Authors: Squizzato A, Agnelli G, Campanini M, Dentali F, Agnelli F, Bonizzoni E, Franco A, Gallo A, Gussoni G, Nitti C, Triolo G, Valerio A, Ventrella F, Fontanella A, FADOI-NoTEVole Study Group Tags: Thromb Haemost Source Type: research

Engineered Micro- and Nanoparticles for Fibrinolysis.
Abstract Fibrinolytic agents including plasmin and plasminogen activators improve outcomes in acute ischemic stroke and thrombosis by recanalizing occluded vessels. In the decades since their introduction into clinical practice, several limitations of have been identified both in terms of efficacy and bleeding risk associated with these agents. Engineered nano- and microparticles address some of these limitations by improving circulation time, reducing inhibition and degradation in circulation, accelerating recanalization, improving targeting to thrombotic occlusions, and reducing off-target effects; however, many...
Source: Thrombosis and Haemostasis - September 15, 2019 Category: Hematology Authors: Disharoon D, Marr DWM, Neeves KB Tags: J Thromb Haemost Source Type: research

Platelet surface expression of cyclophilin A is associated with increased mortality in patients with symptomatic coronary artery disease.
CONCLUSION: CyPA platelet surface expression is associated with mortality whereas CyPA PPIA rs6850 is associated with recurrent MI in patients with symptomatic CAD. CyPA might offer a new biomarker for risk stratification and tailoring therapies in patients with cardiovascular disease. PMID: 31519036 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 12, 2019 Category: Hematology Authors: Rath D, von Ungern-Sternberg S, Heinzmann D, Sigle M, Monzien M, Horstmann K, Schaeffeler E, Winter S, Müller K, Groga-Bada P, Zdanyte M, Borst O, Zernecke A, Gawaz M, Martus P, Schwab M, Geisler T, Seizer P Tags: J Thromb Haemost Source Type: research

Improved Population-Based Clinical Outcomes of Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study.
CONCLUSION:  In the first study of a nationwide population cohort, we show that compliance with the simple ABC pathway is associated with improved clinically relevant outcomes of patients with AF. Given the high health care burden associated with AF, such a streamlined holistic approach to AF management should be implemented, to improve the care of such patients. PMID: 31266082 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 1, 2019 Category: Hematology Authors: Yoon M, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Sung JH, Pak HN, Lee MH, Joung B, Lip GYH Tags: Thromb Haemost Source Type: research

Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study.
CONCLUSIONS: Approximately 2 out of 10 hematological cancer patients experienced MI, ischemic stroke, VTE, or bleeding requiring hospital contact within 10 years. The hematological cancer cohort had higher hazards of MI, ischemic stroke, VTE, and bleeding requiring hospital contact than a general population comparison cohort. This article is protected by copyright. All rights reserved. PMID: 31054195 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 3, 2019 Category: Hematology Authors: Adelborg K, Corraini P, Darvalics B, Frederiksen H, Ording A, Horváth-Puhó E, Rørth M, Sørensen HT Tags: J Thromb Haemost Source Type: research

Hemostatic Genes Exhibit a High Degree of Allele-Specific Regulation in Liver.
CONCLUSION:  Our study provides a comprehensive ASE analysis of hemostatic genes and insights into the regulation of hemostatic genes in human liver. PMID: 31035302 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - April 28, 2019 Category: Hematology Authors: Olsson Lindvall M, Hansson L, Klasson S, Davila Lopez M, Jern C, Stanne TM Tags: Thromb Haemost Source Type: research